Skip to main content Skip to search

YU News

YU News

Webinar Series on Business and Entrepreneurship in Biotech

The Katz School of Science and Health and Albert Einstein College of Medicine are teaming up to host a webinar series on business and entrepreneurship in biotechnology.

“This webinar will highlight trends in the biotechnology industry,” said Dr. Rana Khan, director of the Katz School’s Biotechnology Management and Entrepreneurship master’s program, “and to show what’s involved in commercializing a biotech product or discovery.”

Watch the three discussions below at

Register here to participate:

The three-part series includes discussions on:

  • “Commercializing your Innovation: How to Increase Your Odds of Success,” Thursday, May 20, 4 p.m., presented by Lorraine Marchand, a Katz School biotechnology instructor and vice president and general manager of IBM Watson Health Life Sciences;
  • “What Makes a Fundable Life Science Venture?” Thursday, June 17, 4 p.m., Margalit Haber, an associate with Osage University Partners; and
  • “Perspectives from a European CEO,” Thursday, July 15, at 4 p.m., Nicholas Benedict, CEO and co-founder of Vaderis Therapeutics AG, and Robert Friedman, a Katz School biotechnology instructor and consultant in the life sciences industry.

In addition to being an instructor at Katz, Marchand is responsible for data and AI strategy at Watson Health Life Sciences. She has co-founded two life sciences companies and led development and commercial functions in public and privately held companies, including Bristol-Myers Squibb, Covance, Clinilabs and Cognizant Technology.

Osage University Partners invests in startups that are developing pioneering technologies in partnership with top research institutions in the United States and abroad. Haber focuses on investments in therapeutics, diagnostics and medical devices.

Vaderis Therapeutics, where Benedict is CEO and co-founder, is a biotechnology company based in Switzerland that focuses on the treatment of rare and orphan diseases caused by vascular malformations.

Friedman has held a variety of positions in finance and consulting, and sits on the board of biopharmaceutical firms. His practice has included business strategy and operations assignments in the pharmaceutical, biotech, medical technology and diagnostics industries.

The Katz School’s M.S. in Biotechnology Management and Entrepreneurship program provides students the scientific, technical and business know-how to launch, manage, scale and commercialize biotechnology innovations and delivery systems. The Albert Einstein College of Medicine’s mission is to prepare a diverse body of students to become knowledgeable, compassionate physicians and innovative scientific investigators, and to create new knowledge.